The transporter associated with antigen processing (TAP) is essential for antigen presentation by major histocompatibility complex (MHC) class I molecules. Traditional methods used to analyze peptide transport mediated by TAP require radioactive labeling of peptides and time-consuming manipulation of Concanavalin A-Sepharose. Drug discovery research requires rapid and reliable evaluation of large number of samples for bioactivity. To meet these requirements a nonradioactive, HTS assay for peptide transport activity of TAP has been developed. The radioactive label in the traditional assays has been replaced by a fluorescent label without compromising the transport efficiency of labeled peptide or the sensitivity of the assay. The use of multiscreen filtration plates has facilitated higher throughput and eliminated the centrifugation steps used in traditional TAP assays. The HTS assay shows similar kinetic characteristics as compared to the traditional assay. The HTS assay has been adapted on a Quadra™ 96-32096-channel pipetting station (Tomtec, Hamden, CT) by optimizing time course, dose response of TAP to peptides and adenosine triphosphate (ATP), signal/noise ratio, reproducibility, and reagent stability. This HTS system has been utilized to screen a multiplexed compound library with a maximum of throughput 17,600 compounds per week.
References
1.
Yewdell, J.W., Bennink, J.R. (1992). Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv. Immunol.52:1-123.
2.
Germain, R.N., Margulies, D.H. (1993). The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol.11:403-450.
3.
Benham, A., Tulp, A., Neefjes, J. (1995). Synthesis and assembly of MHC-peptide complexes. Immunol. Today16:359-362.
4.
Bijlmakers, M.J., Ploegh, H.L. (1993). Putting together an MHC class I molecule. Curr. Opin. Immunol.5:21-26.
5.
DeMars, R., Chang, C.C., Shaw, S., Reitnauer, P.J., and Sondel, P.M. (1984). Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum. Immunol.11:77-97.
6.
Kleijmeer, M.J., Kelly, A., Geuze, H.J., Slot, J.W., Townsend, A., Trowsdale, J. (1992). Location of MHC-encoded transporters in the endoplasmic reticulum and cis-Golgi. Nature357:342-344.
7.
Spies, T., DeMars, R. (1991). Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature351:323-324.
8.
de la Salle, H., Hanau, D., Fricker, D., Urlacher, A., Kelly, A., Salamero, J., Powis, S.H., Donato, L., Bausinger, H., et al. (1994). Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science265:237-241.
9.
Yang, Y., Fruh, K., Chambers, J., Waters, J.B., Wu, L., Spies, T., Peterson, P.A. (1992). Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules. J. Biol. Chem.267:11669.
10.
Neefjes, J., Momburg, F., Haemmerling, G.J. (1993). Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science261:769-771.
11.
Ahn, K., Meyer, T.H., Uebel, S., Sempe, P., Djaballah, H., Yang, Y., Peterson, P.A., Fruh, K., Tampe, R. (1996). Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus protein ICP47. EMBO J.15:3247-3255.
